Navigation Links
Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
Date:3/31/2008

Two oral presentations, two poster discussion presentations, three poster

presentations

SOUTH SAN FRANCISCO, Calif., March 31 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that data from clinical trials of the company's investigational compounds XL647, XL184, XL765 and XL880 will be presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30 to June 3, 2008 in Chicago, Illinois. The clinical trial data will be described in two oral presentations (XL184 and XL765), two poster presentations and discussions (XL647), and three poster presentations (XL647 and XL880).

Oral Presentations

-- XL184 (RET, MET, VEGFR2). Data from a phase 1 trial of XL184 in

patients with advanced malignancies, including medullary thyroid

cancer, will be presented on Sunday, June 1, 2008, starting at 10 a.m.

local time (Abstract #3522).

-- XL765 (PI3K, mTOR). Data from a phase 1 trial of XL765 in patients

with advanced solid tumors will be presented on Saturday, May 31,

2008, starting at 1:15 p.m. local time (Abstract #3510).

Poster Presentations and Discussions

-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in

NSCLC patients with acquired resistance to EGFR tyrosine kinase

inhibitors will be presented on Monday, June 2, 2008, during the 8

a.m.-noon session (Abstract #8028).

-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 1 trial of XL647 dosed

daily in patients with advanced solid malignancies will be presented

on Saturday, May 31, 2008, during the 8 a.m.-noon session (Abstract

#3528).

Poster Presentations

-- XL647 (EGFR, HER2, VEGFR2). Data from a phase 2 trial of XL647 in

clinically selected NSCLC patients enriched for the presence of EGFR

mutations will be presented on Sunday, June 1, 2008, during the 2-6

p.m. session (Abstract #8053).

-- XL880* (MET, VEGFR2). Data from a phase 2 trial of XL880 in patients

with papillary renal cell carcinoma will be presented on Saturday, May

31, 2008, during the 8 a.m.-noon session (Abstract #5103).

-- XL880* (MET, VEGFR2). Data from a phase 2 trial of XL880 in MET

amplified, poorly differentiated gastric cancer will be presented on

Monday, June 2, 2008, during the 8 a.m.-2 p.m. session (Abstract

#4572).

* XL880 was selected by GlaxoSmithKline in December 2007 for further

development and commercialization.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Exelixis and the Exelixis logo are registered U.S. trademarks.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
2. Seven Summits Research Releases Alerts on XOM, MER, DRYS, CSC, and PDLI
3. Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference
4. MedImmune Announces Seven Key Promotions and New Hires
5. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
6. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
7. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
8. Jarrow Formulas Launches New Products Featuring BioCell Collagen II(R)
9. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
10. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
11. Option to Develop Exelixis Compound Exercised By Genentech
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... This CAST literature review and report looks at problems ... on the economic effects in countries that are major global commodity exporters and importers, ... resultant risk of low level presence (LLP) puts large volumes of trade worth billions ...
(Date:12/8/2016)...  HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical ... to commercialize innovative therapeutics for patients with cancer, ... approved for trading on the OTCQX U.S. market. ... effective today, under the ticker symbol "HPPI." ... must meet high financial standards, follow best practice ...
(Date:12/8/2016)... Dec. 8, 2016  Partnering to fuel ... Technology Partners of Southeastern Pennsylvania ... parent company of Independence Blue Cross; and Safeguard Scientifics ... intentions for a $6 million funding initiative over a ... Responding to a burgeoning economic vitality in ...
(Date:12/7/2016)... ... 2016 , ... A new study published in the just-published ... advanced pancreatic cancer, liquid biopsies are not yet an adequate substitute for tissue ... sampling may improve the value of a blood-based test.” The study was conducted ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Valencell , the leading innovator in performance ... third consecutive year of triple digit growth for its ... a 360 percent increase in companies who have acquired ... by sales of its wrist and ear Benchmark™ sensor ... for hearables for fitness and healthcare applications. ...
(Date:12/2/2016)... AUSTIN, Texas , Dec. 1, 2016 /PRNewswire/ ... provider, today announced BioLock , an electrocardiogram ... and health monitoring, a key IoT asset. The ... embedded into a vehicle,s steering wheel and mobile ... a simple touch. As vehicle technology ...
(Date:11/29/2016)... 29, 2016   Neurotechnology , a ... recognition technologies, today released FingerCell 3.0, a ... solutions that run on low-power, low-memory microcontrollers. ... less than 128KB of memory, enabling it ... have limited on-board resources, such as: mobile ...
Breaking Biology News(10 mins):